Market Overview

UPDATE: Northland Downgrades ResMed

Share:
Related RMD
The Market In 5 Minutes: Thumbs Up
Benzinga's Top Upgrades

In a note released Tuesday morning, Northland Securities downgraded ResMed (NYSE: RMD) from Market perform to Underperform and maintained its $40 price target.

In the note, Northland analyst cited "numerous forces" in the CPAP space that will squeeze margins and the top-line overtime. Furthermore, the analysts noted that ResMed's model is "highly sensitive" to operating margins and believe that consensus estimates are "unrealistic."

Shares of ResMed are down a little over one percent at $49.44 in Tuesday's trading.

Latest Ratings for RMD

DateFirmActionFromTo
Apr 2016MacquarieUpgradesUnderperformNeutral
Apr 2016Piper JaffrayDowngradesOverweightNeutral
Apr 2016BarclaysInitiates Coverage onUnderweight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Northland SecuritiesDowngrades Price Target Analyst Ratings

 

Related Articles (RMD)

View Comments and Join the Discussion!